Evidence map›Paper›PMID 39352717›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

A Dual-Adjuvanted Parenteral-Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS-CoV-2 in Mice.

Bhawana Pandey, Zhengying Wang, Angela Jimenez, Eshant Bhatia, Ritika Jain, Alexander Beach, Drishti Maniar, Justin Hosten, Laura O'Farrell, Casey Vantucci and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bhawana PandeyWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0003-4090-2618
Zhengying WangWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Angela JimenezWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Eshant BhatiaWoodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Ritika JainWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Alexander BeachWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Drishti ManiarWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Justin HostenWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Laura O'FarrellPhysiological Research Laboratory, Georgia Institute of Technology, Atlanta, GA, USA.
Casey VantucciWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
David HurWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Richard NoelPhysiological Research Laboratory, Georgia Institute of Technology, Atlanta, GA, USA.
Rachel RingquistThe Parker H. Petit Institute for Bioengineering and Biosciences, School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Clinton SmithWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Miguel A OchoaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Krishnendu RoyWallace H. Coulter Department of Biomedical Engineering, The Parker H. Petit Institute for Bioengineering and Biosciences, Marcus Center for Therapeutic Cell Characterization and Manufacturing, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0002-9972-0950

Funding

Effect of presentation methods on the molecular mechanism of combinatorial adjuvantsU01AI124270 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI ROY, KRISHNENDU · 2016 to 2020
$3.3M
Georgia Tech FoundationNational Institutes of Health- National Institute of Allergy and Infectious Disease U01-AI124270NIAID NIH HHS U01 AI124270Robert A. Milton Chaired Professorship to Krishnendu Roy
6 · The paper itself

Abstract

Existing parenteral SARS-CoV-2 vaccines produce only limited mucosal responses, essential for reducing transmission and achieving sterilizing immunity. Appropriately designed mucosal boosters can overcome the shortcomings of parenteral vaccines and enhance pre-existing systemic immunity. Here, a new protein subunit nanovaccine is developed by utilizing dual-adjuvanted (RIG-I: PUUC RNA and TLR-9: CpG DNA) polysaccharide-amino acid-lipid nanoparticles (PAL-NPs) along with SARS-CoV-2 S1 trimer protein, that can be delivered both intramuscularly (IM) and intranasally (IN) to generate balanced mucosal-systemic SARS-CoV-2 immunity. Mice receiving IM-Prime PUUC+CpG PAL subunit nanovaccine, followed by an IN-Boost, developed high levels of IgA, IgG, and cellular immunity in the lungs and showed robust systemic humoral immunity. Interestingly, as a purely intranasal subunit vaccine (IN-Prime/IN-Boost), PUUC+CpG PAL-NPs induced stronger lung-specific T cell immunity than IM-Prime/IN-Boost, and a comparable IgA and neutralizing antibodies, although with a lower systemic antibody response, indicating that a fully mucosal delivery route for SARS-CoV-2 vaccination may also be feasible. The data suggest that PUUC+CpG PAL subunit nanovaccine is a promising candidate for generating SARS-CoV-2 specific mucosal immunity.

Indexed as

Administration, IntranasalCOVID-19COVID-19 VaccinesImmunity, MucosalNanoparticlesSARS-CoV-2Vaccines, SubunitAdjuvants, ImmunologicAdjuvants, VaccineAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleMiceMice, Inbred BALB CNanovaccinesAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesNanovaccinesSpike Glycoprotein, CoronavirusVaccines, Subunitantiviral immunitycombination adjuvantsmucosal immunityparenteral and intranasal vaccinationpolymer nanoparticlesSARS‐CoV‐2 subunit nanovaccine

Identifiers

PMID39352717
PMCPMC11615772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.